322 related articles for article (PubMed ID: 35885067)
21. Immunotherapy and Response Assessment in Malignant Glioma: Neuro-oncology Perspective.
Bagley SJ; Desai AS; Nasrallah MP; O'Rourke DM
Top Magn Reson Imaging; 2020 Apr; 29(2):95-102. PubMed ID: 32271286
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
23. Irradiation of pediatric glioblastoma cells promotes radioresistance and enhances glioma malignancy
Alhajala HS; Nguyen HS; Shabani S; Best B; Kaushal M; Al-Gizawiy MM; Erin Ahn EY; Knipstein JA; Mirza S; Schmainda KM; Chitambar CR; Doan NB
Oncotarget; 2018 Sep; 9(75):34122-34131. PubMed ID: 30344926
[TBL] [Abstract][Full Text] [Related]
24. CD44-associated radioresistance of glioblastoma in irradiated brain areas with optimal tumor coverage.
Liu WH; Lin JC; Chou YC; Li MH; Tsai JT
Cancer Med; 2020 Jan; 9(1):350-360. PubMed ID: 31746135
[TBL] [Abstract][Full Text] [Related]
25. Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma.
Wang Y; Li S; Peng Y; Ma W; Wang Y; Li W
Cancer Innov; 2023 Apr; 2(2):114-130. PubMed ID: 38090060
[TBL] [Abstract][Full Text] [Related]
26. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
27. Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Wang J; Zuo J; Wahafu A; Wang MD; Li RC; Xie WF
CNS Neurosci Ther; 2020 Mar; 26(3):297-308. PubMed ID: 31318172
[TBL] [Abstract][Full Text] [Related]
28. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Bielecka-Wajdman AM; Lesiak M; Ludyga T; Sieroń A; Obuchowicz E
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1249-1256. PubMed ID: 28500556
[TBL] [Abstract][Full Text] [Related]
29. Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond.
Daisy Precilla S; Kuduvalli SS; Thirugnanasambandhar Sivasubramanian A
Cell Biol Int; 2021 Jan; 45(1):18-53. PubMed ID: 33049091
[TBL] [Abstract][Full Text] [Related]
30. Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells.
Vengoji R; Ponnusamy MP; Rachagani S; Mahapatra S; Batra SK; Shonka N; Macha MA
Carcinogenesis; 2019 Mar; 40(1):2-14. PubMed ID: 30475990
[TBL] [Abstract][Full Text] [Related]
31. Glioblastoma cells incorporate into tumor vasculature and contribute to vascular radioresistance.
Shaifer CA; Huang J; Lin PC
Int J Cancer; 2010 Nov; 127(9):2063-75. PubMed ID: 20162571
[TBL] [Abstract][Full Text] [Related]
32. Narrative review of palliative hypofractionated radiotherapy for high grade glioma.
Saeed H; Tseng YD; Lo SS
Ann Palliat Med; 2021 Jan; 10(1):846-862. PubMed ID: 33040565
[TBL] [Abstract][Full Text] [Related]
33. Novel Therapies for Glioblastoma.
Liu EK; Sulman EP; Wen PY; Kurz SC
Curr Neurol Neurosci Rep; 2020 May; 20(7):19. PubMed ID: 32445058
[TBL] [Abstract][Full Text] [Related]
34. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Yahyanejad S; King H; Iglesias VS; Granton PV; Barbeau LM; van Hoof SJ; Groot AJ; Habets R; Prickaerts J; Chalmers AJ; Eekers DB; Theys J; Short SC; Verhaegen F; Vooijs M
Oncotarget; 2016 Jul; 7(27):41251-41264. PubMed ID: 27183910
[TBL] [Abstract][Full Text] [Related]
35. Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma.
Kang H; Lee S; Kim K; Jeon J; Kang SG; Youn H; Kim HY; Youn B
J Exp Clin Cancer Res; 2021 Sep; 40(1):282. PubMed ID: 34488821
[TBL] [Abstract][Full Text] [Related]
36. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
[TBL] [Abstract][Full Text] [Related]
38. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
39. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
40. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis.
Marenco-Hillembrand L; Wijesekera O; Suarez-Meade P; Mampre D; Jackson C; Peterson J; Trifiletti D; Hammack J; Ortiz K; Lesser E; Spiegel M; Prevatt C; Hawayek M; Quinones-Hinojosa A; Chaichana KL
J Neurooncol; 2020 Apr; 147(2):297-307. PubMed ID: 32157552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
